Compositions and Methods of Treating Facioscapulohumeral Muscular Dystrophy (2022)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 63/245,123, filed Sep 16, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,912,779 | Compositions and Methods of Treating Facioscapulohumeral Muscular Dystrophy In force · High confidence | Avidity Biosciences, Inc. | In force | High confidence | ||
| US 12,071,485 | Compositions and Methods of Treating Facioscapulohumeral Muscular Dystrophy In force · High confidence | Avidity Biosciences, Inc. | In force | High confidence | ||
| US 12,157,774 | Compositions and Methods of Treating Facioscapulohumeral Muscular Dystrophy In force · High confidence | Avidity Biosciences, Inc. | In force | High confidence | ||
| US 12,486,328 | Compositions and Methods of Treating Facioscapulohumeral Muscular Dystrophy In force · Medium confidence | Avidity Biosciences, Inc. | In force | Medium confidence | ||
| Application 18/809,215 | Compositions and Methods of Treating Facioscapulohumeral Muscular Dystrophy Pending Not granted | Avidity Biosciences, Inc. | Pending | Not granted |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Avidity Biosciences, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.